Literature DB >> 23204169

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

Gregory A Raczniak1, Lisa R Bulkow, Michael G Bruce, Carolyn L Zanis, Richard L Baum, Mary M Snowball, Kathy K Byrd, Umid M Sharapov, Thomas W Hennessy, Brian J McMahon.   

Abstract

The Centers for Disease Control and Prevention recommends hepatitis A virus (HAV) vaccination for all children at age 1 year and for high-risk adults. The vaccine is highly effective; however, protection duration is unknown. We report HAV antibody concentrations 17 years after childhood immunization, demonstrating that protective antibody levels remain and have stabilized over the past 7 years.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23204169      PMCID： PMC3611760          DOI： 10.1093/infdis/jis710

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  12 in total

1.  Hepatitis a vaccination coverage among adolescents in the United States.

Authors:  Christina G Dorell; David Yankey; Kathy K Byrd; Trudy V Murphy
Journal:  Pediatrics       Date:  2012-01-23       Impact factor: 7.124

2.  Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children.

Authors:  Guo-Lin Bian; Rui Ma; Hong-Jun Dong; Hong-Xia Ni; Feng-Jiao Hu; Yao-Rong Chen; Jia-Qun Chen; Shao-Ying Zhou; Yong-Xin Lin; Guo-Zhang Xu
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

3.  Long-term follow-up of hepatitis A vaccination in children.

Authors:  C Y Chan; S D Lee; M I Yu; Y J Wang; F Y Chang; K J Lo
Journal:  Vaccine       Date:  1999-01-28       Impact factor: 3.641

4.  Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age.

Authors:  Pierre van Damme; Froukje Kafeja; Marie Van Der Wielen; Maarten Leyssen; Jeanne-Marie Jacquet
Journal:  Pediatr Infect Dis J       Date:  2011-08       Impact factor: 2.129

5.  Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years.

Authors:  P C Fan; M H Chang; P I Lee; A Safary; C Y Lee
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

6.  Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years.

Authors:  Koen Van Herck; Jeanne-Marie Jacquet; Pierre Van Damme
Journal:  J Med Virol       Date:  2011-08-23       Impact factor: 2.327

7.  A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

Authors:  B J McMahon; M Beller; J Williams; M Schloss; H Tanttila; L Bulkow
Journal:  Arch Pediatr Adolesc Med       Date:  1996-07

8.  Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska.

Authors:  Rosalyn J Singleton; Sarah Hess; Lisa R Bulkow; Louisa Castrodale; Ginger Provo; Brian J McMahon
Journal:  Vaccine       Date:  2010-07-15       Impact factor: 3.641

9.  Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska.

Authors:  Dolly Peach; Brian J McMahon; Lisa Bulkow; Elizabeth Funk; Rafael Harpaz; Harold S Margolis
Journal:  J Infect Dis       Date:  2002-09-20       Impact factor: 5.226

10.  Secular trends in hepatitis A virus infection among Alaska Natives.

Authors:  L R Bulkow; R B Wainwright; B J McMahon; J P Middaugh; S A Jenkerson; H S Margolis
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226
View more
  11 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Caregivers who refuse preventive care for their children: the relationship between immunization and topical fluoride refusal.

Authors:  Donald L Chi
Journal:  Am J Public Health       Date:  2014-05-15       Impact factor: 9.308

3.  Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line.

Authors:  Erxia Yang; Chen Cheng; Ying Zhang; Jingjing Wang; Yanchun Che; Jing Pu; Chenghong Dong; Longding Liu; Zhanlong He; Shuaiyao Lu; Yuan Zhao; Li Jiang; Yun Liao; Congwen Shao; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-02-28       Impact factor: 3.452

4.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

5.  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.

Authors:  Philip R Spradling; Lisa R Bulkow; Susan E Negus; Chriss Homan; Michael G Bruce; Brian J McMahon
Journal:  Hepatology       Date:  2016-02-01       Impact factor: 17.425

6.  The Impact of Vaccination Efforts on the Spatiotemporal Patterns of the Hepatitis A Outbreak in Michigan, 2016-2018.

Authors:  Andrew F Brouwer; Jonathan L Zelner; Marisa C Eisenberg; Lynsey Kimmins; Macey Ladisky; Jim Collins; Joseph N S Eisenberg
Journal:  Epidemiology       Date:  2020-09       Impact factor: 4.860

Review 7.  Hepatitis B and A vaccination in HIV-infected adults: A review.

Authors:  G Mena; A L García-Basteiro; J M Bayas
Journal:  Hum Vaccin Immunother       Date:  2015-07-24       Impact factor: 3.452

Review 8.  Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Authors:  Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

Review 9.  A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region.

Authors:  Selim Badur; Serdar Öztürk; Alev Ozakay; Mansour Khalaf; Debasish Saha; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2021-07-02       Impact factor: 4.526

10.  Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22-23 March 2012.

Authors:  David FitzSimons; Brian McMahon; Greet Hendrickx; Alex Vorsters; Pierre Van Damme
Journal:  Int J Circumpolar Health       Date:  2013-07-17       Impact factor: 1.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.